Diseases

AbelZeta Pharma Announces Clinical Data Presentation for C-CAR168 at ACR Convergence 2025

Strategic Insights

Oct 19, 2025 — 1 min read

AbelZeta Pharma, a global clinical-stage biopharmaceutical company, announced that clinical data from the first-in-human Phase I trial of C-CAR168 in patients with refractory autoimmune diseases will be presented at the American College of Rheumatology (ACR) Convergence 2025. The presentation, titled "Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases," will highlight the potential of C-CAR168 in achieving "immune reset" and sustained drug-free remission in refractory autoimmune diseases.

Key Takeaways:

C-CAR168 is an autologous anti-CD20/BCMA bispecific Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to target autoantibody-producing plasma cells and their B-cell precursors.
The Phase I trial (NCT06249438) will be presented at ACR Convergence 2025 as a late-breaking poster presentation.
AbelZeta Pharma is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland, and Shanghai, China.
The company is developing innovative and proprietary cell-based therapeutic products, including CAR-T therapies, to treat hematological malignancies, solid tumors, and inflammatory and immunological diseases.
C-CAR168 aims to achieve "immune reset" and sustained drug-free remission in refractory autoimmune diseases.
The company's pipeline comprises CAR-T therapies, and it advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies.

Statistics:

The Phase I trial of C-CAR168 has enrolled patients with refractory autoimmune diseases.
The presentation at ACR Convergence 2025 will take place on Tuesday, October 28, 10:30 AM - 12:30 PM CT, in Hall F1, McCormick Place.
AbelZeta Pharma has a presence in Rockville, Maryland, and Shanghai, China.
The company's pipeline comprises CAR-T therapies, a type of immunotherapy that harnesses the body's own immune system to fight against diseases.

Sources:

PRNewswire
AbelZeta Pharma, Inc.

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients